Methods for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
- inclusion criteria
- SIC scoring/diagnostics
- statistical analysis
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
Evaluation of other predictors of 28-day mortality pertaining to clotting factors and heparin treatment
SIC score interpretation for COVID-19
Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group
Learn After
Inclusion criteria for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Statistical analysis for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
SIC score and diagnostics for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China